A small, light-activated molecule recently tested in mice represents a new approach to eliminating clumps of amyloid protein found in the brains of Alzheimer’s disease patients. If perfected in humans, the technique could be used as an alternative approach to immunotherapy and used to treat other diseases caused by similar amyloids.
Researchers injected the molecule directly into the brains of live mice with Alzheimer’s disease and then used a specialized probe to shine light into their brains for 30 minutes each day for one week. Chemical analysis of the mouse brain tissue showed that the treatment significantly reduced amyloid protein. Results from additional experiments using human brain samples donated by Alzheimer’s disease patients supported the possibility of future use in humans.
“The importance of our study is developing this technique to target the amyloid protein to enhance clearance of it by the immune system,” said Yukiko Hori, a lecturer at the University of Tokyo and co-first author of the research recently published in Brain.
The small molecule that the research team developed is known as a photo-oxygenation catalyst. It appears to treat Alzheimer’s disease via a two-step process.
First, the catalyst destabilizes the amyloid plaques. Oxygenation, or adding oxygen atoms, can make a molecule unstable by changing the chemical bonds holding it together. Laundry detergents or other cleaners known as “oxygen bleach” use a similar chemical principle.
The catalyst is designed to target the folded structure of amyloid and likely works by cross-linking specific portions called histidine residues. The catalyst is inert until it is activated with near-infrared light, so in the future, researchers imagine that the catalyst could be delivered throughout the body by injection into the bloodstream and targeted to specific areas using light.
Second, the destabilized amyloid is then removed by microglia, immune cells of the brain that clear away damaged cells and debris outside healthy cells. Using mouse cells growing in a dish, researchers observed microglia engulfing oxygenated amyloid and then breaking it down in acidic compartments inside the cells.
“Our catalyst binds to the amyloid-specific structure, not to a unique genetic or amino acid sequence, so this same catalyst can be applied to other amyloid depositions,” said Professor Taisuke Tomita, who led the project at the University of Tokyo.
The American Society of Clinical Oncology estimates that each year in the U.S., 4,000 people are diagnosed with diseases caused by amyloid outside of the brain, collectively known as amyloidosis.
The photo-oxygenation catalyst should be capable of removing amyloid protein, regardless of when or where it formed in the body. Although some existing Alzheimer’s disease treatments can slow the formation of new amyloid plaques, eliminating existing plaques is especially important in Alzheimer’s disease because amyloid begins aggregating years before symptoms appear.
The research team is now working to modify the design of the catalyst so it can be activated by shining light through the skull.
More from: University of Tokyo
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Reducing amyloid protein
- Biogen inc (BIIB) Q3 2021 Earnings Call Transcript
Q3 2021 Earnings CallOct 20, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning. My name is Shelby and I will be your ...
- Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
Monoclonal antibodies targeting key epitopes within the N-terminus of Aβ have demonstrated that reducing amyloid plaque burden ... antibody that targets tau, a protein implicated in diseases ...
- Trafficking of Cell-Surface β-Amyloid Precursor Protein: Evidence that a Sorting Intermediate Participates in Synaptic Vesicle Recycling
We recently demonstrated that the Alzheimer’s β-amyloid precursor protein (APP) is internalized from the axonal cell surface. In this study, we use biochemical and cell biological methods to ...
- Alzheimer’s Mystery Solved: How Amyloid Beta Forms in Brain Nerve Cells
In a major breakthrough, researchers at Massachusetts General Hospital (MGH) have discovered how amyloid beta — the neurotoxin believed to be at the root of Alzheimer's disease (AD) — forms in axons ...
- Researchers discover how gum disease can cause dementia
The results showed a key receptor protein, which carries amyloid ... They discovered the therapy succeeded in reducing the volume of amyloid beta in infected cells by 40 percent.
Go deeper with Google Headlines on:
Reducing amyloid protein
Go deeper with Bing News on:
- Intellia Therapeutics' NTLA-2001 to treat transthyretin amyloidosis granted orphan drug status by USFDA
Cambridge: Intellia Therapeutics, Inc., has recently announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of ...
- Tafamidis stabilizes transthyretin in cohort with transthyretin amyloid cardiomyopathy
CardioOncology, in unselected patients, serum transthyretin change after tafamidis initiation for transthyretin amyloid cardiomyopathy may serve as a surrogate measure of drug efficacy.“Transthyretin ...
- US FDA grants orphan drug status to Intellia Therapeutics’ NTLA-2001 to treat transthyretin amyloidosis
US FDA grants orphan drug status to Intellia Therapeutics’ NTLA-2001 to treat transthyretin amyloidosis: Cambridge, Massachusetts Saturday, October 23, 2021, 13:00 Hrs [IST] Int ...
- Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
Intellia NTLA and partner Regeneron REGN announced that the FDA has granted Orphan Drug designation (“ODD”) to their CRISPR genome-editing candidate, NTLA-2001, for the treatment of transthyretin ...
- Intellia Gets FDA Orphan Designation for NTLA-2001 in ATTR Amyloidosis >NTLA
Intellia Therapeutics Inc. on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to NTLA-2001 for the treatment of transthyretin, or ATTR, amyloidosis. The ...